UChicago Medicine

https://www.uchicagomedicine.org/

 

6th Annual Updates from ASH 2020
05:11

UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Updates on R/R MM: How to Choose Amongst Available Regimens at 1st Relapse? What Is the Current Non-Cellular Therapy Landscape for Triple Refractory Disease?

FEATURING Ben Derman
  • 258 views
  • March 16, 2021
  • 1
21:25

UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Updates on Frontline MM: What Is the Optimal Induction Regimen? Is It a One-Size-Fits-All Approach? Should Transplant Be Pursued? Multi-Drug vs. Single-Drug Maintenance

FEATURING Ben Derman
  • 316 views
  • March 16, 2021
  • 2
11:49

UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

35 y/o Male With Newly Diagnosed ALL: What Findings Are Traditionally Associated With Worse Outcomes? What Is the Most Appropriate Choice of Initial Therapy? How to Follow Response to Therapy?

FEATURING Adam Duvall, Peter Riedell, Ben Derman, Satyajit Kosuri
  • 29 views
  • March 8, 2021
15:12

UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

63 y/o Male With MCL: What Initial Therapy to Choose? What Would Be the Preferred 2L Therapy & Beyond?

FEATURING Adam Duvall, Peter Riedell, Ben Derman, Satyajit Kosuri
  • 230 views
  • March 8, 2021
  • 1
17:01

UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

Newly Diagnosed MM Case Discussion: Classifying Patient Risk, and Approaches to Induction Therapy and Transplant

FEATURING Adam Duvall, Peter Riedell, Ben Derman, Satyajit Kosuri
  • 202 views
  • March 8, 2021
14:37

UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

Expert Analysis of a Primary Myelofibrosis Case: What Tests Could Be Helpful? How to Approach Progression? How to Approach a Patient With MPN-AP/BP With an IDH1/2 Mutation?

FEATURING Adam Duvall, Peter Riedell, Ben Derman, Satyajit Kosuri
  • 99 views
  • March 8, 2021
24:46

UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Updates on Non-Malignant Hematology: Mycophenolate for ITP, CTX001 in Patients With TDT & SCD, Tranexamic Acid for Thrombocytopenia

FEATURING Michael Thirman
  • 13 views
  • March 8, 2021
34:05

UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Practice Changing Updates in AML: Maintenance Oral Aza, Lower Intensity Combos With Aza & HMA + Ven in Newly Diagnosed AML, Ven + Gilteritinib & Menin Inhibitor in R/R Disease

FEATURING Courtney D. DiNardo
  • 122 views
  • March 8, 2021
  • 1
30:26

UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Advances in Cellular Therapy: Tisa-Cel in R/R B-ALL, Blinatumomab Sequencing in ALL, BiTES for DLBCL, Selection/Sequencing of CAR-T vs. BiTE, Brexu-Cel in R/R MCL, BCMA-Targeting in Myeloma

FEATURING Andrzej Jakubowiak
  • 28 views
  • March 8, 2021
27:46

UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Highlights on High-Risk MDS in HMA Era: Oral HMAs, BCL2 Inhibition, Macrophage Checkpoint Inhibition, TP53 Modulators

FEATURING Olatoyosi Odenike
  • 18 views
  • March 8, 2021
16:45

UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

Best of ASH on SCT in Leukemias: Who Should Be Referred Early for ASCT? Does MRD Status Matter? What Is the Role of HMA + Ven? Who Should Consider Maintenance Therapy w/o Consolidative alloSCT?

FEATURING Satyajit Kosuri
  • 82 views
  • March 8, 2021
16:23

UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Update on SCT for Myeloid and Lymphoid Leukemias: Apamistamab as Part of the Conditioning Regimen, Ruxolitinib for SR-aGVHD, Enasidenib as Post-Transplant Maintenance, Venetoclax Mono, Targeted T-Cell Maintenance

FEATURING Satyajit Kosuri
  • 61 views
  • March 8, 2021
17:31

UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Updates on SoC in Lymphomas: How Beneficial Are Newly Approved BT + Polatuzumab & Tafa + Len in R/R DLBCL? Are Bispecific Antibodies Active in B-NHL?

FEATURING Peter Riedell
  • 153 views
  • March 7, 2021
  • 1
07:31

UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Updates on cHL: 2L Pembro + GVD, Brentuximab Vedotin & Checkpoint Blockade Combination in High Risk Patients

FEATURING Peter Riedell
  • 109 views
  • March 5, 2021
06:44

UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Updates on SoC in R/R MCL: How Active Are Novel BTKi & CAR-T Therapies?

FEATURING Peter Riedell
  • 21 views
  • March 5, 2021